@LearningEachDay SI confirmed on the webcast they are having discussions with several big Pharma in regard to CHF. Basically he is looking to combine the great mortality and lower event rates from Revascor with other treatments that have shown lower hospitalization rates (MSB's unfortunate conservative primary end-point). I strongly urge people to listen to the webcast:
https://webcast.boardroom.media/mesoblast-limited/20201214/NaN5fd6e483de11ae0019f60917
The written release was terrible by contrast to this excellent insight into the results and has been taken too literally by the market. SI makes the point that the mortality and event secondary endpoints will be far more important to the FDA and potential partners.
@LearningEachDay SI confirmed on the webcast they are having...
-
- There are more pages in this discussion • 707 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 26954 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |